BioAsia 2016 – Hyderabad
BioAsia 2016 Hyderabad:
Bio Asia 2016, the international life sciences convention, will be held from February 8-10 at HICC, Hyderabad. The thirteenth edition of the prestigious event is organized by the Industries and Commerce Department in partnership with Government of India, Federation of Asian Biotech Associations (FABA) and Pharmaceutical Export Promotion Council (Pharmexcil).
‘Seen widely as a catalyst for the life sciences industry, providing a platform for B2B meetings, advocating policies and discussing the roadmap for the Industry, BioAsia event has emerged as the biggest event in the country in every perspective, in terms of footfalls, B2B meetings, business transactions, working group discussions, participation of global thought leaders etc.,’ an excerpt from the official website says. The theme of this year’s conference is ‘Leveraging India to Succeed Globally.’
Theme of BioAsia 2016:
With increasing pressure to reduce drug development costs and accelerate R&D programs, the global companies have started setting up R&D centres in Asia to take advantage of cost-effective, yet highly skilled talent pool. India has emerged as a preferred destination for contract research and manufacturing activities, process reengineering and innovative R&D to act as a single destination with various enablers in place. The country is aided by a large, highly skilled community of scientists and researchers. Additionally, the government’s support in bringing a comprehensive IPR Policy, launch of ‘Make in India’ and financial support programs, regulatory reforms, etc. are expected to further boost the growth for Life Sciences industry.
Under this backdrop, the thirteenth edition of BioAsia will be organized with the theme of Leveraging India to Succeed globally and shall focus on connecting the dots to build stakeholder consensus and draw a distinct road-map to propel the sector growth.
Advantage India and Hyderabad BioAsia 2016:
The Indian life sciences industry is on the threshold of entering a New Era of growth and positivity, promising extraordinary growth and an innovation driven bioeconomy. The Indian biotechnology sector is one of the fastest growing knowledge based sectors in India and is expected to play a key role in shaping India’s rapidly developing economy. With numerous comparative advantages in terms of R&D facilities, knowledge skills and cost effectiveness, the biotechnology industry in India is fast emerging as a Global Leader.
Leading the world: India is among the top six producers of pharmaceuticals in the world
World Renowned Quality: Approx. 1,297 WHO GMP standard manufacturing units.
A Pharma Hub: Over 10,500 manufacturing units & over 3,000 pharma companies growing at an exceptional rate.
Affordable Quality: Manufacturing costs are approx. 35-40% of those in the US due to low installation & manufacturing costs.
Growing Capabilities: Large pool of scientific talent at a reasonable cost
Dedicated to Excellence: 19 dedicated pharmaceutical SEZs at various stages.
- Front Runner in Life Science Innovation and Manufacturing in the Country
- About 33% of the vaccines produced globally are from Hyderabad
- Inherent strengths in basic and advanced sciences (including chemistry, biology, IT, etc.), concentration of activities across verticals, and disease profile enables seamless forward and backward linkages / integration for product development including clinical development and translational research.
- Availability of ready to occupy facilities in various sizes with common facilities and large bank of land
- High quality ecosystem with rich talent pool puts Hyderabad ahead
Life Sciences Hub – Conducive Ecosystem
Biotech: Houses India’s largest and only systematically developed biotech cluster – the Genome Valley
Pharma: Pharma Capital of India -Accounts for about 35-40% of India’s pharma production
BioAgri: Seed Capital of India – Houses Country’s first translational platform
Medtech: India’s first Medical Devices Park with common facilities and incubation services
Services: Significant number of CROs/CMOs, vivarium, and testing laboratories easing the outsourcing
Source: BioAsia 2016.